Entrada Therapeutics, Inc.
TRDA
$6.37
$0.111.76%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -39.72M | -39.16M | -44.13M | -43.10M | -17.35M |
| Total Depreciation and Amortization | 805.00K | 886.00K | 1.23M | 1.03M | 946.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.20M | 3.73M | 4.38M | 4.09M | 3.75M |
| Change in Net Operating Assets | -6.98M | 2.35M | 10.21M | 8.49M | -25.85M |
| Cash from Operations | -41.70M | -32.20M | -28.31M | -29.49M | -38.51M |
| Capital Expenditure | -44.00K | 207.00K | 171.00K | -275.00K | -1.14M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 27.03M | 28.91M | 48.94M | 34.07M | 5.93M |
| Cash from Investing | 26.99M | 29.12M | 49.11M | 33.80M | 4.78M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 100.00K | 192.00K | 8.00K | 337.00K | 350.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.00K | 192.00K | 8.00K | 337.00K | 350.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.61M | -2.89M | 20.80M | 4.65M | -33.37M |